Recombinant Human Hu R/A protein

Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.

N-terminal histidine tag

-20°C

Recombinant Human Hu R/A protein, derived from the transfected human HEK293 cells.

ELAVL1

Lyophilized from a 0.2 µm filtered solution in PBS

Hu R/A protein, ELAV Like RNA Binding Protein 1, ELAV (Embryonic Lethal, Abnormal Vision, Drosophila)-Like 1 (Hu Antigen R), Embryonic Lethal, Abnormal Vision, Drosophila, Homolog-Like 1, Hu Antigen R, Hu-Antigen R, HUR, ELAV-Like Protein 1, ELAV1, MelG, Hua.

His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)

Briefly spin the vial and bring the contents to the bottom prior to opening. It is recommended to reconstitute at 0.5 - 1.0 mg/mL with sterile deionized water.

Figure 1. Deglycosylation of purified recombinant proteins. Purified proteins were untreated (Lane 2) or treated with Protein Deglycosylation Kit under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated. Lane 1: Protein standard ladder (kDa) Lane 2: Untreated protein under reducing conditions Lane 3: Treated protein with deglycosylation enzymes under native conditions Lane 4: Treated protein with deglycosylation enzymes under reducing conditions.Lane 5: Deglycosylation mixture only without target proteins.